Ontology highlight
ABSTRACT:
SUBMITTER: Xie C
PROVIDER: S-EPMC5694459 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
Frontiers in pharmacology 20171114
KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogenic driver with mutations in 30% of non-small cell lung cancer (NSCLC). However, there is no effective clinical drug even though it has been identified as an oncogene for 30 years. In this study, we identified a small molecule inhibitor compound 0375-0604 targeting KRAS by using molecular docking based virtual screening approach. Compound 0375-0604 had a good binding affinity to KRAS <i>in vitro</i> and exhibited cytotoxicit ...[more]